Skip to main content
60°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptinyx Inc
(NQ:
APTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 18, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptinyx Inc
< Previous
1
2
Next >
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
March 30, 2023
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
February 27, 2023
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Present at the SVB Securities Global Biopharma Conference
January 31, 2023
From
Aptinyx Inc.
Via
Business Wire
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
November 10, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
November 08, 2022
From
Aptinyx Inc.
Via
Business Wire
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
November 03, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 18, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
August 25, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
August 12, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
August 04, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
July 15, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
June 22, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
May 18, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
May 17, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
May 12, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
April 29, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 27, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
April 20, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
April 07, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
March 23, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
February 28, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
February 09, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 08, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Announces Formation of Scientific Advisory Board
February 03, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
January 06, 2022
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
December 20, 2021
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
December 16, 2021
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 13, 2021
From
Aptinyx Inc.
Via
Business Wire
Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021
From
Aptinyx Inc.
Via
Business Wire
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 09, 2021
From
Aptinyx Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.